Efficacy and Safety of Combined Antimycotic Therapy of Invasive Aspergillosis in Children | CMAC

Efficacy and Safety of Combined Antimycotic Therapy of Invasive Aspergillosis in Children

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):383-388

​ Kolbin A.S., Boichenko E.G., Ilyina N.A., Kolb Z.K., Klimko N.N.
invasive aspergillosis children combination antifungal therapy voriconazole caspofungin
Section
Personal experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):383-388

Abstract

Invasive aspergillosis is a common complication in children with hemoblastosis. This type of mycosis characterized with severe clinical presentations and high attributive mortality. Monotherapy with one of the systemic antimycotics is often using to treat invasive aspergillosis. During last years several reports concerning efficacy of combined therapy with different antifungal agents were published. The authors analyze their own experience of treating invasive aspergillosis with caspofungin and voriconazole combination in child with hemoblastosis, and also review a literature data.

  • 1. Abbasi S., Shener J., Hughes W., et al. Aspergillosis in children with cancer: 34-year experience. Clin Infect Dis 1999; 29:1210.
  • 2. Denning D. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
  • 3. Patterson T., Kirkpatrick W., White M., et al. Invasive aspergillosis – disease spectrum, treatment practices, and outcomes. Medicine 2000; 79:250-60.
  • 4. Gilbert D., Moellering R., Epiopoulos G., Sande M., editors. The Sanford guide to antimicrobial therapy (thirty-sixth edition). USA; 2006.
  • 5. Steinbach W. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005; 5:203-10.
  • 6. Ascioglu S., Rex J., Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an internation consensus. Clin Infect Dis 2002; 34:7-14.
  • 7. Перечень основных методов и критериев диагностики микозов. Климко Н.Н., Васильева Н.В., Елинов Н.П. и др. - СПб.:00, 2001.-24 с.
  • 8. Patterson T., Kirkpatrick W., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000; 79:250-60.
  • 9. Steinbach W. Combination antifungal therapy for invasive aspergillosis - Is it indicated? Med Mycol 2006;44:373-82.
  • 10. Jeu L., Piacenti F., Lyakhovetskiy A., et al. Voriconazole. Clin Ther 2003; 25:1321-81.
  • 11. Wong-Beringer A., Jacobs R., Guglielmo B. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-18.
  • 12. Patterson T. Treatment of invasive aspergillosis: polyenes, echinocandins, or azoles? Med Mycol 2006; 44:357-62.
  • 13. Groll A., Walsh T. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10:1545-58.
  • 14. Deresinski S., Stevens D. Caspofungin. Clin Infect Dis 2003; 36:1445-57.
  • 15. Lewis R., Kontoyiannis D. Rationale for combination antifungal therapy. Pharmacotherapy 2001; 21:149-164.
  • 16. Antoniadou A., Kontoyiannis D. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 2003; 16:539-45.
  • 17. Marr K. Combination antifungal therapy: where are we now and where are we going? Oncology 2004; 18:24-9.
  • 18. Steinbach W., Stevens D., Denning D. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37:188-224.
  • 19. Nivoix Y., Zamfir A., Lutun P., et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006; 52:67-74.
  • 20. Kontoyiannis D., Hachem R., Lewis R., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-9.
  • 21. Aliff T., Maslak P., Jurcic J., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-32.
  • 22. Marr K., Boeckh M., Carter R., et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
  • 23. Singh N., Limaye A., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
  • 24. Cesaro S., Toffolutti T., Messina C., et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73:505.
  • 25. Rosen-Wolff A., Koch A., Friedrich W., et al. Successful elimination of an invasive Aspergillus nidulans lung infection by voriconazole after failure of a combination of caspofungin and liposomal amphotericin B in a boy with chronic glaucomatous disease. Pediatr Infect Dis J 2004; 23:584-6.
  • 26. Schuster F., Moelter C., Schmid I., et al. Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer 2005; 44:682-5.
  • 27. Elanjikal Z., Sorensen J., Schmidt H., et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22:653-6.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared